Sun Pharma enters definitive agreement for all-cash acquisition of Organon at an enterprise value of $11.75 billion, paying $14.00 per share.
The acquisition, subject to regulatory and stockholder approval, aims to create a top-25 global pharma company with combined revenue of $12.4 billion.
Strategic rationale includes entry into biosimilars, strengthening women's health portfolio, and nearly doubling EBITDA and cash flow post-integration.
Transaction funded via available cash and committed bank financing, expected to close in early 2027, creating a more diversified global platform.